A 75-year-old man with a genetic predisposition for Alzheimer’s has yet to show signs of the disease. Could this offer ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

A Potential Solution for Neurodegenerative Diseases. Open Access Library Journal, 12, 1-16. doi: 10.4236/oalib.1112714 . Alzheimer’s Disease (AD), a complex neurodegenerative condition, significantly ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Art Still has ATTR amyloidosis, an inherited heart condition that dramatically impacts Black men and the former Kansas City ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.